Maxicuma®

Joint health study

Efficacy at an
ultra low dose.

“Efficacy and safety investigation of LIMAN technology based curcumin formulation on knee osteoarthritis: a randomized double-blind placebo-controlled trial.”Published · European Journal of Integrative Medicine 79 (2025) 102531

Study design.

Design
Randomised, double-blind, placebo-controlled trial
Participants
180 adults with mild to moderate knee osteoarthritis
Intervention
Maxicuma® at 100 or 250 mg a day, or placebo, for 90 days
Measured
Pain (VAS), WOMAC scores (total, stiffness and physical function) and a treadmill walk test, at days 30, 45, 60 and 90

Key outcomes.

Joint health, by day 90Change from baseline; p < 0.0001 vs placebo100 mg250 mg
Reduction in pain score (VAS)
70%
79%
Lower WOMAC total score
70%
79%
Reduction in WOMAC stiffness score
72%
80%
Improved mobility (physical performance)
93%
131%

The results.

PainVisual analogue scale, lower is better
Pain on the visual analogue scale over 90 days: placebo, Maxicuma 100 mg and 250 mg010203040506070BaselineDay 30Day 45Day 60Day 90Pain, VAS score********
PlaceboMaxicuma® 100 mgMaxicuma® 250 mg

Significant from day 30 at both doses. *p < 0.0001 vs placebo.

WOMAC totalPain, stiffness and physical function, lower is better
WOMAC total (pain, stiffness, physical function) over 90 days05101520253035BaselineDay 30Day 45Day 60Day 90WOMAC total score********
PlaceboMaxicuma® 100 mgMaxicuma® 250 mg

Significant from day 30 at both doses. *p < 0.0001 vs placebo.

StiffnessWOMAC stiffness domain, lower is better
WOMAC stiffness over 90 days: placebo, Maxicuma 100 mg and 250 mg0.00.51.01.52.02.53.0BaselineDay 30Day 45Day 60Day 90WOMAC stiffness score********
PlaceboMaxicuma® 100 mgMaxicuma® 250 mg

Lower stiffness score at both doses from day 30. *p < 0.001 vs placebo.

Treadmill walkDistance travelled without pain, higher is better
Treadmill walk: distance travelled without pain over 90 days050100150200250300BaselineDay 30Day 45Day 60Day 90Distance without pain, m********
PlaceboMaxicuma® 100 mgMaxicuma® 250 mg

Improved mobility at both doses. *p < 0.0001 vs placebo.

Also measured.

In a preclinical study, published in Sage Journals:

  • Antioxidant support: higher serum SOD and catalase.
  • Cartilage support: lower cartilage oligomeric matrix protein and glycosaminoglycans, and higher COL2A1.
  • Joint health support: lower MMP3 and MMP7, proteins involved in the metabolism of joint tissue.
  • Anti-inflammatory support: lower COX-2, PGE2, C-reactive protein and IL-10.

Single-dose and 28-day repeated-dose toxicity studies found Maxicuma® safe at the human equivalent dose, published in the Journal of Biologically Active Products from Nature.

No clinically meaningful safety concerns: safe for use.

The publication.

Girish HR, Harshith N, Chalichem NSS, Phanindra A, Khan MS, Deshpande J. “Efficacy and safety investigation of LIMAN technology based curcumin formulation on knee osteoarthritis: a randomized double-blind placebo-controlled trial.” European Journal of Integrative Medicine 79 (2025) 102531.

Full text available on request.

Request the full text About Maxicuma®

The other Maxicuma® study

Pharmacokinetic study · Published

Higher uptake of curcuminoids

Current Research in Complementary & Alternative Medicine, 2023

14 adults · equal dose · vs micronized curcumin 95%

Read the study

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Next step

Working with Maxicuma®?

Tell us the format and the market, and we will send a sample with its specification.

Request a sample

Download the Maxicuma® brochure

A few details, and the download starts.